Title: Treatment of Melanoma by Reduction in Clusterin Levels. Number: 20040082534. Filed: Aug. 21, 2003. Lead Inventor: Martin Gleave, Vancouver General Hospital.
The patent application, its abstract states, covers the treatment of melanoma through “reduction in the effective amount of clusterin in melanoma cells … in a mammalian subject, preferably a human.”
The abstract states that “the therapeutics agent may be … a small inhibitory RNA [compound] targeted to clusterin. Bcl-xL in a subject or cell line can also be regulated by administering … an agent effective to modulate the amount of clusterin expression.”
The abstract adds that “such inhibition is significant because bcl-xL is known to act as an inhibitor of apoptosis.”
Title: Cctra Gene as a Tool to Produce Male-Only Progeny in the Mediterranean Fruitfly Ceratitis capitata. Number: 20040082032. Filed: Sept. 8, 2003 (PCT Filed: March 8, 2002). Lead Inventor: Pasquale Delli Bovi, Università di Napoli.
According to the patent application’s abstract, the invention”refers to the identification of the Cctra gene and to corresponding dsRNA molecules comprising Cctra gene sequences as a tool to produce only-male progeny in the Mediterranean fruitfly Ceratitis capitata.